Fast™
Identification of at-risk NASH patients
Learn more
NewFibroScan® GO
The state-of-the-art non-invasive solution, affordable to all.
Powered by LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.
Supported by 3,500+ peer reviewed publications and 160+ guidelines.
An affordable and cost-effective solution…
Pay per exam offer.
All services included.
…to improve liver health management
Early detection of patients at risk.
Simple, quick, non-invasive and painless examination
that can be performed by any trained operator.
Interpretation tools and calculation of clinical scores
to support in making instant medical decisions for patients.
Diagnosis and follow-up of the progression of the disease.
A comprehensive solution designed for the office-based practice
Perform the examination with FibroScan® and its interpretation
to determine the fibrosis stage and the steatosis grade.
Calculate FIB-4 and Combined Scores.
Generate consolidated and personalized medical reports.
Consult and visualize the history of your patients’ results.
Tried & Trusted
FibroScan® is perfect for use in a primary care setting, it is portable and gives patients an instant result enabling them to leave with the result.
Fibroscan® is key to providing a Community service, which is part of the wider pathway to increase early detection and timely intervention and management of patients with and at-risk of liver disease.
FibroScan® as an interventional therapy helps primary care physicians and nurse specialists engage patients by demonstrating the results and outcomes as a value change.
Peace of mind with pro-active and dedicated support
Assists you with onsite installation and training.
Includes maintenance, calibration of probes and software updates.
Easy access to continuous training and users community with Echosens Academy.
A state-of-the-art FibroScan®
Quickly and easily assess liver stiffness using LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.1,2,3
FibroScan® 230 is a Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). This device is designed for use in a medical practice in order to provide liver stiffness measurement at 50 Hz shear wave frequency and liver ultrasonic attenuation (CAP) at 3.5 MHz ultrasound frequency. Liver stiffness and CAP are indicated as an aid to diagnosis and monitoring for adult and pediatric patients as part of an overall assessment of liver disease. Examinations with FibroScan® 230 device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. FibroScan®, among others, are trademarks and/or service mark of Echosens Group.
All personal and health data generated by the FibroScan® GO solution is managed in compliance with HDS and RGPD regulations. Data located on Echosens Cloud is managed by an ISO27001 certified organization.
1. Wong VW, et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478.
2. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
3. Steadman R, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158.
Already a FibroScan GO® user?
To access the FibroScan® 230 user guides, connect to the Echosens Cloud
Learning Center > FibroScan® GO